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Transcatheter Aortic
Valve Implantation
Could It Be Done Without
Prior Balloon Valvuloplasty?*
Alec Vahanian, MD, Dominique Himbert, MD
Paris, France
Transcatheter aortic valve implantation (TAVI) was intro-
duced 8 years ago for the treatment of aortic stenosis and
has since spread worldwide, with over 30,000 cases per-
formed. Current evidence suggests that TAVI is the best
option for inoperable patients and represents a reasonable
alternative in high-risk patients for whom a heart team
chooses TAVI over surgery (1,2). Balloon aortic valvulo-
plasty (BAV), which previously had limited indications
because of its limited efficacy in improving the natural
history of the disease, has experienced a revival with the
development of TAVI as part of the procedure.
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Over time, the TAVI technique has been refined due to
the increased experience of operators and improvements in
technology. There is a trend toward simplification of the
transfemoral procedure moving from general anesthesia and
surgical vascular access to sedation, local anesthesia, and a
full percutaneous approach. It is in this context that the
paper by Grube et al. (3) in this issue of JACC: Cardiovas-
cular Interventions proposes, for the first time, to perform
TAVI without BAV, which has been recommended as a
preliminary step (2).
This study is a pilot multicenter series of 60 patients who
underwent TAVI using the self-expandable Medtronic
CoreValve (MCV) (Medtronic, Minneapolis, Minnesota)
device via a transfemoral approach. The results obtained
with the “simplified approach” were compared with a
historical control group; however, the value of this compar-
ison suffers from several methodological limitations and will
not be taken into account during the rest of the discussion.
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BAV can be used as a rehearsal, before the final phase of
positioning and releasing the prosthesis, allowing a final
assessment of the effectiveness of rapid pacing to lower the
transaortic flow. This step is crucial when using the balloon
expandable prostheses and of less importance with the
MCV.
Aortography during BAV enables a final measurement of
the aortic annulus in cases where doubts persist as regards
the choice of the size of the prosthesis after echocardiogra-
phy and/or multislice computed tomography.
BAV “cracks” the nodular calcification and stretches the
aortic wall, which may have several advantages for the sub-
sequent performance of TAVI: easier crossing of the heavily
calcified valve by the device and better deployment of the
stented valve allowing for better hemodynamics and less
paravalvular regurgitation. This “preparation” was no doubt
important for crossing the valve when using the first-
generation devices of 24- to 26-F. However, in the present
series, the low profile of the 18-F MCV device allowed for
an easy crossing because technical success was high (97%).
The radial force of the device was sufficient, in itself, to
obtain satisfactory post-implantation mean gradients and
valve areas. By contrast, the findings in this study do not
show convincingly that the simplified approach carries an
acceptable risk of aortic regurgitation (AR). Overall, the
incidence of any regurgitation seems in line with the ex-
pected number (AR was present in 82% of cases), but the
frequency of moderate AR (57%) appears high, even more
so when taking into account the need for post-dilation in
17% of cases, mostly for AR 2. In this respect, the
design of the study does not allow firm conclusions as
regards the comparison with the standard technique, which
would require a centralized evaluation of AR and a random-
ized design that could also take into account the degree of
calcification and the distribution of calcium, which may
have an impact. In addition, it is not possible to extrapolate
the findings obtained here with MCV, where the valve is
supra-annular and may theoretically be less affected by a
suboptimal deployment at the level of the aortic annulus,
to the balloon-expandable prosthesis where the valve is
intra-annular.
Conversely, the avoidance of BAV before TAVI may
have several advantages:
Reducing the duration of the procedure should always be
aimed at in this elderly and high-risk population especially
if general anesthesia is used. However, performing BAV is
not the longest part of TAVI; it takes only a few minutes.
Another theoretical advantage is the reduction in costs in
cases where no redilation is needed, but this has a limited
impact on the global cost of TAVI, which, currently, is
largely driven by the price of the prostheses.
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759Not performing BAV may avoid any need for rapid
pacing, which could be deleterious in patients with very
poor left ventricular function. This remark is not applicable
to balloon expandable valves where pacing is mandatory.
Finally, there are specific balloons that can be used to
perform BAV without pacing.
More importantly, even if the risks of BAV are now
reduced in comparison with historical series, BAV carries a
risk that may add to that of TAVI and that should not be
underestimated in this population (4–6). This does not
concern the vascular complications because most teams
perform BAV when the large sheath, which will be used for
introduction of the prosthesis, is already in place.
The risk of stroke is around 2%, conversely the additional
manipulations for crossing the native valve without dilation
may increase this risk. Tamponade, which may be due to
annular rupture, may occur in 1% to 2% of patients. It is
speculative to say that annular rupture, which occurs during
BAV before TAVI would not have occurred during implan-
tation of the prosthesis itself, if sizing is properly done.
Tamponade may also result from perforation related to
manipulation of the stiff guidewire positioned in the apex of
the left ventricle. BAV seldom induces severe AR (2%),
which could be poorly tolerated and could compromise the
hemodynamic condition if TAVI is not speedily performed,
the prosthesis being ready before BAV has been started.
The trend is now to perform BAV with an undersized
balloon to avoid these 2 latter complications.
BAV may induce, per se, aortic valve block. This should
not compromise the performance of TAVI if pacing is
readily available. It is difficult, from the data in the litera-
ture, to know exactly how BAV-induced aortic valve blocks
play a role in the overall pacemaker implantation; however,
the U.K. registry shows that balloon pre-dilation is inde-
pendently associated with the need for pacemaking after
TAVI (7).
Overall, Grube et al. (3) should be congratulated for, once
again, pioneering a new procedural step in the short, but
very lively, history of TAVI. This pilot study is provocative
in suggesting a further simplification of TAVI. However,
the conclusions as regards the efficacy and risks of the
“simplified approach” versus the standard approach are onlypreliminary due to the limited number of patients included,
and the nonrandomized design of the study. In addition, the
findings of this pilot study using the MCV device should
not be automatically translated to the other commercially
available device, even if its profile is also 18-F, as the
principle, that is, balloon-expandable versus self-expandable
prosthesis, is different.
Thus, TAVI can be done without balloon pre-dilation
when using the MCV device; however, it is not yet
established if it should be done. In addition, BAV is likely
to remain as a bridge to TAVI in unstable patients, in those
with uncertain indication (5,6), or for after dilation in
certain circumstances of underdeployment after TAVI.
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